Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Shareholder Meeting (April 2016)
15 slides from Trendlines's shareholder meeting presentation, Apr 19, 2016
Slide 1: SGX General Announcement: AGM Presentation April 2016
Issuer/Manager THE TRENDLINES GROUP LTD. Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T Stapled Security No Announcement Title General Announcement Date & Time of Broadcast 19-Apr-2016 07:12:56 Status New Announcement Subtitle Trend lines Annual General Meeting Presentation (April 2016) A
Slide 2: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Annual General Meeting 19 April 2016 1
Slide 3: Legal Disclaimer
Legal Disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 4: Trendlines: Innovation Commercialization
Trendlines: Innovation Commercialization The Trendlines Group invents, discovers, invests in, and incubates, life science companies in the fields of medical and agricultural technologies. Israeli Government-Franchised Incubators Invest in life sciences companies Internal Innovation Center Invents an
Slide 5: More Than 500 Opportunities Reviewed Annually
More Than 500 Opportunities Reviewed Annually Sources of Deal Flow Israel, United States; expanding to Singapore, Germany, China • Entrepreneurs • Inventors • Universities and research institutions • Needs identified by industry partners We Look For • Leaders with passion and commitment • Unmet need
Slide 6: From Seed to Success at High Speed
Trendlines: From Seed to Success at High Speed Year 3+ Path to Exit Year Governance 2 Follow-on funding Business development Ideation Due Diligence Year Follow-On Funding Commercialization 1 Preclinical / clinical trials Investment banking Proof of Concept Regulatory submission R&D to prototype Mark
Slide 7: Financial Highlights
Trendlines: Financial Highlights (US$ 000) FY2012 FY2013 FY2014 FY2015 Total Portfolio Fair Value* 74,639 77,494 85,776 Total Income 13,768 29,707 8,553 9,939 Non-GAAP Total Expenses before non- 5,158 6,798 11,408 7,938 recurring, non-cash item Non-GAAP Income/(Loss) before income 8,610 22,909 (2,85
Slide 8: Value Creation
Trendlines: Value Creation US$000 Portfolio Value 100,000 90,000 80,000 70,000 60,000 50,000 40,000 Portfolio companies are 30,000 like tightly wound springs; 20,000 value-building events 10,000 release significant “energy” i.e., jumps in value - 31.12.12 31.12.13 31.12.14 31.12.15 Portfolio Value *
Slide 9: Consistently Building Value
Trendlines: Consistently Building Value US$ 000 Portfolio Value 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 31.12.07 31.12.08 31.12.09 31.12.10 31.12.11 31.12.12 31.12.13 31.12.14 31.12.15 Portfolio Value * * Includes fair market value of assets carried at equity value 8
Slide 10: Trendlines' Recent Developments
Trendlines’ Recent Developments Bayer AG and Trendlines form Bayer Trendlines Agtech Innovation Fund with $US10 million investment from Bayer Definitive collaboration agreement with B. Braun Melsungen AG Trendlines Labs collaboration framework agreement with a Japanese multinational medical device c
Slide 11: Trendlines and Israel's Office of the Chief Scientist (OCS)
Trendlines and Israel’s Office of the Chief Scientist (OCS) Trendlines Medical received new 8-year license in January 2016 from OCS. Agtech incubator license expires in June 2016. Single Israeli Government license allows us to: Continue developing existing agritech portfolio companies Continue to in
Slide 12: Our Business Strategies
Our Business Strategies Follow-On Investments in Portfolio Companies • Accelerate portfolio company development • Demonstrate support and confidence • Limit dilution Expansion into New Markets Exploring international opportunities, including in Singapore, Germany, and China Expansion of Trendlines L
Slide 13: Highlights From the DBS Vickers Reports
Highlights From the DBS Vickers Reports Strong track record of raising follow-on funding for 75% of portfolio companies and successful sale of 5 portfolio companies or their assets since 2011 Strong growth prospects in medtech and agtech • Aging population and growing demand for sophisticated medica
Slide 14: Traded Peer Group & Industry Comparables
Trendlines: Traded Peer Group & Industry Comparables As at 13 April 2016 SGD Last price 0.220 IPO price 0.330 52wk high 0.395 52wk low 0.133 Market cap 109.3 million Shares outstanding 508.8 million Price to Portfolio (FMV)* Allied Minds (LSE:ALM) 2.40 Imperial Innovations (AIM:IVO) 1.73 IP Group (L
Slide 15: Thank You!
Thank You! Todd Dollinger, Chairman & CEO todd@trendlines.com +972.72.260.7000 | www.trendlines.com Steve Rhodes, Chairman & CEO steve@trendlines.com 14 10 April 2016
The Trendlines Group — Shareholder Meeting (April 2016) on 6ix